Accelerated Pharma (Accelerated Pharma) EBIT : $-1.98 Mil (TTM As of Mar. 2017)

View and export this data going back to 2016. Start your Free Trial

What is Accelerated Pharma EBIT?

Accelerated Pharma's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2017 was $-0.36 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2017 was $-1.98 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Accelerated Pharma's annualized ROC % for the quarter that ended in Mar. 2017 was -40.87%. Accelerated Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2017 was -19,253.33%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Accelerated Pharma EBIT Historical Data

The historical data trend for Accelerated Pharma's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerated Pharma EBIT Chart

Accelerated Pharma Annual Data

Trend

Dec14

Dec15

Dec16

EBIT

-3.54

-3.10

Accelerated Pharma Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17
EBIT	Get a 7-Day Free Trial			-1.48	-0.54	-0.65	-0.43	-0.36

Competitive Comparison of Accelerated Pharma's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Accelerated Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Accelerated Pharma's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Accelerated Pharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Accelerated Pharma's EV-to-EBIT falls into.

Accelerated Pharma EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.98 Mil.

Accelerated Pharma (NAS:ACCP) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Accelerated Pharma's annualized ROC % for the quarter that ended in Mar. 2017 is calculated as:

	ROC % (Q: Mar. 2017 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2016 )	+	Invested Capital (Q: Mar. 2017 ))	/ count )
=	-1.64 * ( 1 - 0% )	/	( (3.81	+	4.215)	/ 2 )
=	-1.64	/	4.0125
=	-40.87 %

where

	Invested Capital		(Q: Dec. 2016 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.147	-	1.611	-	( 0.062	-	max(0, 5.339	-	0.065	+	0.062	))
=	3.81

	Invested Capital		(Q: Mar. 2017 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.198	-	1.879	-	( 0.063	-	max(0, 5.961	-	0.065	+	0.063	))
=	4.215

Note: The Operating Income data used here is four times the quarterly (Mar. 2017) data.

2. Joel Greenblatt's definition of Return on Capital:

Accelerated Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2017 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2017 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2016		Q: Mar. 2017
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-1.444	/	( ( (0.008 + max(-1.956, 0))	+	(0.007 + max(-2.274, 0)) )	/	2 )
=	-1.444	/	( ( 0.008	+	0.007 )	/	2 )
=	-1.444	/	0.0075
=	-19,253.33 %

where Working Capital is:

	Working Capital		(Q: Dec. 2016 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.003)	-	(1.611	+	0	+	0.348)
=	-1.956

	Working Capital		(Q: Mar. 2017 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.002)	-	(1.879	+	0	+	0.397)
=	-2.274

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2017) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Accelerated Pharma's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2017 )
	=	-1.976	/	0.000
	=	%

Accelerated Pharma EBIT Related Terms

Thank you for viewing the detailed overview of Accelerated Pharma's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Accelerated Pharma (Accelerated Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Accelerated Pharma Inc (NAS:ACCP) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Accelerated Pharma Inc, is a Delaware corporation organized on May 12, 2014. It is a biopharmaceutical company focused on utilizing its genomic technology to enhance the development and commercialization of pharmaceutical products. Its lead product candidate is Picoplatin, a new generation platinum-based cancer therapy that has the potential for use in different formulations, as a single agent or in combination with other anti-cancer agents, to treat multiple cancer indications.

Accelerated Pharma (Accelerated Pharma) Headlines

No Headlines